May 3, 2021 | News, Press Releases
The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be an effective treatment for severe, chronic PTSD 67% of participants who received three MDMA-assisted therapy sessions no longer qualified for a PTSD...Mar 17, 2021 | News, Press Releases
Widespread anecdotal reports of benefit have led to self-treatment of the symptoms of posttraumatic stress disorder (PTSD) with cannabis among Veterans and others; the safety and potential efficacy of such treatments have not previously been studied through randomized...Dec 7, 2020 | News, Press Releases
Cognitive-behavioral conjoint therapy (CBCT) for posttraumatic stress disorder (PTSD), when combined with MDMA, resulted in significant improvements in PTSD symptoms Six couples, in which one partner was diagnosed with PTSD, participated in a seven-week protocol; both...Dec 2, 2020 | News, Press Releases
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support...Nov 24, 2020 | News, Press Releases
Pilot study explored the application of MDMA-assisted psychotherapy in 18 individuals experiencing moderate to severe anxiety following diagnosis with a life-threatening illness The primary outcome, change in State-Trait Anxiety Inventory (STAI) Trait Scores,...Oct 14, 2020 | News, Press Releases
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients Santa Cruz, CA, October 14, 2020 – A peer-reviewed study published today in the research journal...